Business
Tandem Diabetes Care Study Demonstrates Improvements of All Clinical Endpoints in Adults with Type 2 Diabetes Using Control-IQ Technology
SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, announced results from a
About this update from Tandem Diabetes Care, Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nTandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, announced results from a prospective, multicenter, single-arm study of adults living with type 2 diabetes who achieved improvement in all clinical endpoints with the use of the t:slim X2 insulin pump with Control-IQ technology.1\n\nPresented today at the 22nd Annual Diabetes Technology Meeting, the data demonstrated the system to be safe during 6 weeks of use, with a substantial improvement in time in range and mean glucose related to a reduction in hyperglycemia and no increase in continuous glucose monitor (CGM)-measured hypoglycemia.* Both prior multiple daily injection (MDI) users and prior basal insulin only users showed similar levels of improvement. Study participants indicated a high level of satisfaction with the system.\n\n“Our goal with this study was to show Control-IQ technology was safe and could offer considerable benefit to individuals with type 2 diabetes, and we accomplished that,” said Carol Levy, MD, CDCES, protocol chair for the study and Professor of Medicine (Division of Endocrinology, Diabetes and Bone Disease) at the Icahn School of Medicine at Mount Sinai. “The 15 percent time in range improvement from prior therapy represents a 3.6 hour/day increase in time in range, with no hypoglycemia events.”\n\n“The results presented today are consistent with numerous studies that support the benefits of pump therapy to people who live with type 2 diabetes,” said Jordan Pinsker, MD, Vice President and Medical Director for Tandem Diabetes Care. “People living with type 2 diabetes often take other medications in combination with their insulin therapy. The combination of safety outcomes and high satisfaction scores seen in this population, who were able to continue these existing medications during the study, shows that Control-IQ technology could be a powerful management solution for their therapy needs.\"\n\nPrimary Outcomes\n\nGlycemic Control\n\n\nUse of Control-IQ technology was demonstrated to be safe during 6 weeks of use\n\n\nMean time in range across all participants improved 15 percentage points, an increase of 3.6 hours per day\n\n\nMean time in range for prior MDI/pump users improved 16 percentage points\n\n\nMean time in range for prior Basal-only insulin users improved 13...